JP2022523663A - 放射線処置および/または放射線模倣剤処置を伴う、肝損傷を緩和し、肝臓の肥厚、再生、および細胞の生着を促進するための方法 - Google Patents

放射線処置および/または放射線模倣剤処置を伴う、肝損傷を緩和し、肝臓の肥厚、再生、および細胞の生着を促進するための方法 Download PDF

Info

Publication number
JP2022523663A
JP2022523663A JP2021542408A JP2021542408A JP2022523663A JP 2022523663 A JP2022523663 A JP 2022523663A JP 2021542408 A JP2021542408 A JP 2021542408A JP 2021542408 A JP2021542408 A JP 2021542408A JP 2022523663 A JP2022523663 A JP 2022523663A
Authority
JP
Japan
Prior art keywords
subject
liver
administered
radiation
hepatocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021542408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523663A5 (cg-RX-API-DMAC7.html
Inventor
アイヘンバウム,ゲイリー
グハ,チャンダン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montefiore Medical Center
Original Assignee
Montefiore Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montefiore Medical Center filed Critical Montefiore Medical Center
Publication of JP2022523663A publication Critical patent/JP2022523663A/ja
Publication of JP2022523663A5 publication Critical patent/JP2022523663A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1049—Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021542408A 2019-01-25 2020-01-24 放射線処置および/または放射線模倣剤処置を伴う、肝損傷を緩和し、肝臓の肥厚、再生、および細胞の生着を促進するための方法 Ceased JP2022523663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796806P 2019-01-25 2019-01-25
US62/796,806 2019-01-25
PCT/US2020/014934 WO2020154585A1 (en) 2019-01-25 2020-01-24 Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments

Publications (2)

Publication Number Publication Date
JP2022523663A true JP2022523663A (ja) 2022-04-26
JP2022523663A5 JP2022523663A5 (cg-RX-API-DMAC7.html) 2024-08-16

Family

ID=69740558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542408A Ceased JP2022523663A (ja) 2019-01-25 2020-01-24 放射線処置および/または放射線模倣剤処置を伴う、肝損傷を緩和し、肝臓の肥厚、再生、および細胞の生着を促進するための方法

Country Status (12)

Country Link
US (1) US20200237871A1 (cg-RX-API-DMAC7.html)
EP (1) EP3914272B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523663A (cg-RX-API-DMAC7.html)
KR (1) KR20210141460A (cg-RX-API-DMAC7.html)
CN (1) CN113766926A (cg-RX-API-DMAC7.html)
AU (1) AU2020211412A1 (cg-RX-API-DMAC7.html)
CA (1) CA3127455A1 (cg-RX-API-DMAC7.html)
ES (1) ES2978584T3 (cg-RX-API-DMAC7.html)
IL (1) IL285094A (cg-RX-API-DMAC7.html)
MA (1) MA54820A (cg-RX-API-DMAC7.html)
MX (1) MX2021008943A (cg-RX-API-DMAC7.html)
WO (1) WO2020154585A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7481252B2 (ja) 2017-07-26 2024-05-10 ヤンセン ファーマシューティカ エヌ.ベー. 標的放射線治療誘発性血管完全性を保護する方法
CN113018424B (zh) * 2019-12-25 2023-05-02 中国科学院分子细胞科学卓越创新中心 Cst1在预防和/或治疗肝脏免疫失调疾病中的应用
CN118660955A (zh) * 2021-10-01 2024-09-17 詹森药业有限公司 增加祖细胞生产的方法
EP4525907A2 (en) * 2022-05-20 2025-03-26 JANSSEN Pharmaceutica NV Methods for mitigating lung injury in conjunction with exposure to radiation and/or radiation or radiomimetic treatments
CA3265726A1 (en) * 2022-08-24 2024-02-29 Montefiore Medical Center Bifunctional FLT3 ligand molecules for thrombocytopenia and acute radiation syndrome
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20020147158A1 (en) * 2001-02-27 2002-10-10 University Of Southern California Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
RS20060141A (sr) 2003-08-28 2008-08-07 Ortho-Mcneil Pharmaceutical Inc., Peptidi i jedinjenja koja se vežu za receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
PT1984014E (pt) 2006-02-14 2014-11-13 Janssen Pharmaceutica Nv Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia
JP2010511631A (ja) * 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物
KR20110015448A (ko) 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 tpo 모방 펩티드
MX2011008936A (es) * 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
JP2018503654A (ja) * 2015-01-27 2018-02-08 サイファーム ソシエテ ア レスポンサビリテ リミテSciPharmS.a r.l. 肝静脈閉塞症の処置のための組成物
JP7481252B2 (ja) * 2017-07-26 2024-05-10 ヤンセン ファーマシューティカ エヌ.ベー. 標的放射線治療誘発性血管完全性を保護する方法
US20200237872A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GANGIREDDY, V. G. ET AL.: "Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis", DIGESTIVE DISEASES AND SCIENCES, vol. 57, no. 9, JPN6024004458, 2012, pages 2466 - 2472, ISSN: 0005255161 *
WILLEMART, S. ET AL.: "Acute radiation-induced hepatic injury: evaluation by triphasic contrast enhanced helical CT", THE BRITISH JOURNAL OF RADIOLOGY, vol. 73, no. 869, JPN6024004457, 2000, pages 544 - 546, ISSN: 0005255162 *

Also Published As

Publication number Publication date
ES2978584T3 (es) 2024-09-16
AU2020211412A1 (en) 2021-08-12
CA3127455A1 (en) 2020-07-30
EP3914272A1 (en) 2021-12-01
WO2020154585A9 (en) 2020-09-17
WO2020154585A1 (en) 2020-07-30
US20200237871A1 (en) 2020-07-30
KR20210141460A (ko) 2021-11-23
MA54820A (fr) 2021-12-01
MX2021008943A (es) 2021-11-04
IL285094A (en) 2021-09-30
EP3914272B1 (en) 2024-03-06
CN113766926A (zh) 2021-12-07

Similar Documents

Publication Publication Date Title
EP3914272B1 (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
JP2022523663A5 (cg-RX-API-DMAC7.html)
JP6613312B2 (ja) 膵臓癌を処置するためのペプチドをベースとする方法
JP2012503014A (ja) マルチ−peg化顆粒球コロニー刺激因子(g−csf)変異体の投与による放射線誘発好中球減少症の処置のための方法
CN111432845B (zh) 保护靶向放射治疗诱导下的血管完整性的方法
JP7664163B2 (ja) 全身照射/化学曝露に対する応答において臓器および血管損傷、造血回復ならびに生存に対する保護を増強する方法
Cranmer et al. Rodent models of brain metastasis in melanoma
Hansen et al. Liposome accumulation in irradiated tumors display important tumor and dose dependent differences
HK40064882A (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
HK40064882B (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
US20250312417A1 (en) Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments
US20220265871A1 (en) Method of Treating Cancer by Intratumoral Deposition of Radioactive Microparticles
JP2021501750A (ja) 骨髄細胞の保護のためのアルファ−1−ミクログロブリンの使用
金尚昊 Allogeneic peripheral blood stem cell transplantation using nonmyeloablative pretransplant conditioning regimen in dogs
Dong et al. Efficacy and safety of 32P-nanocolloid for treatment of distant lymph node metastasis in VX2 tumor-bearing rabbits
Lung 19 The Lung, Pleura, and Thymus
Miyauchi The Role of Neuropilin 1 in Glioma Associated Microglia and Macrophages
Rachmawati et al. Modification of Interleukin-10 with Mannose-6-Phosphate Groups Yields a Liver-Specific Cytokine with Antifibrotic Activity in Rats
Ozzello Kari Cantell, 3 Roberto L. Ceriani, 2 and David V. Habif, Sr. 1 1 College of Physicians and Surgeons, Columbia University

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240705

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250617

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251028